Predictive Technology Group, Inc. of Salt Lake City has acquired FlagshipHealth Group, a Minneapolis-based provider of sales and consulting services for the healthcare industry. Predictive Technology markets data analytics for disease identification and subsequent therapeutic intervention through biotechnology treatments.
{mprestriction ids="1,3"}The business combination provides essential resources for Predictive Technology Group to develop, launch and grow its services directed at limiting disease and improving the health and well-being of individuals confronting a wide range of medical conditions, the company said in a release. Since February 2017, Flagship has provided sales and marketing support for the launch of treatments offered by Predictive Technology Group’s wholly owned subsidiary, Predictive Biotech. FlagshipHealth worked with another Predictive subsidiary, Predictive Therapeutics, toward commercialization of the ARTGuide, a genetic diagnostic for endometriosis and other concerns addressed in fertility clinics, and FertilityDx Services, a test suite delivering personalized and comprehensive genetic diagnostic services to couples undergoing infertility care.
“We are very pleased to have the team at Flagship join the Predictive organization,” said Bradley Robinson, CEO of Predictive Technology Group. “As we move forward to fully address important challenges, such as endometriosis, and our efforts in regenerative health interventions, the team at Flagship demonstrates a tremendous understanding of the complexity and stakeholder diversity within healthcare delivery, finance and administration. With the expansion of our products and services addressing significant medical problems confronting individuals and families throughout the world and our imminent commercialization of diagnostics and therapeutics for endometriosis, it became obvious that the integration of our two organizations better serves patients, care providers and shareholders.”
“We have enjoyed working closely with Predictive since our introduction in 2010 and through Predictive Biotech’s regenerative medicine commercialization in 2017,” said Tim Lacy, Flagship president and founder. “We are excited to transition Flagship from a long-time advisory partner into a permanent contributor to the Predictive family.”{/mprestriction}
